Amphion Innovations PLC Related Party Transaction (2529T)

TIDMAMP

RNS Number : 2529T

Amphion Innovations PLC

11 October 2017

Amphion Innovations plc

("Amphion" or "the Company")

Related Party Transaction

Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, provides further details on the Deed of Postponement as announced on 29 September 2017 in the Company's interim results.

Certain directors of the Company, being Richard Morgan and Robert Bertoldi (the "Directors"), entered into a Deed of Postponement with the Company on 15 May 2017 where they agreed to postpone the repayment of the amounts owed to them by the Company as at 31 December 2016, which total US$4.3 million, plus any interest which may accrue thereon ("Director Debt") until all other debts of the Company are repaid. Furthermore, the Directors agreed that any amount owed by the Company other than the Director Debt (the "Debt") shall rank for all purposes and at all times ahead of the Director Debt.

Richard Morgan and Robert Bertoldi are directors of the Company and have an interest in approximately 23,642,499 and 6,436,431 Ordinary Shares respectively (representing an interest of approximately 11.39% and 3.10% of the Existing Ordinary Shares respectively). By virtue of Mr Morgan and Mr Bertoldi being directors in addition to Mr Morgan's current interests in the Company, the Directors are considered to be a related party as defined under the AIM Rules. Thus, entering into the Deed of Postponement constitutes a related party transaction for the purposes of Rule 13 of the AIM Rules.

The independent directors, being Richard Mansell-Jones and Miroslaw Izienicki, consider, having consulted with the Company's nominated adviser, Panmure Gordon, that the terms of the Deed of Postponement as entered into by the Company with the Directors are fair and reasonable insofar as the Company's Shareholders are concerned.

For further information please contact:

 
 Amphion Innovations                           Tel: +1 (212) 210 6224 
 Charlie Morgan 
 
 Panmure Gordon Limited (Nominated                     Tel: +44 (0)20 
  Adviser and Corporate Broker)                             7886 2500 
 Freddy Crossley / Duncan Monteith 
  (Corporate Finance) 
 Charlie Leigh-Pemberton 
  (Corporate Broking) 
 
 Northland Capital Partners                       Tel: +44 (0)20 3861 
  Limited (Joint Corporate Broker)                               6625 
 Patrick Claridge / David 
  Hignell (Corporate Finance) 
 John Howes (Corporate 
  Broking) 
 
 Walbrook PR                                 Tel: +44 (0)20 7933 8780 
                                                                   or 
 Mike Wort/ Paul McManus                       amphion@walbrookpr.com

About Amphion Innovations plc

Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in 7 Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number which grows rapidly each year.

On the web: www.amphionplc.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLFFFIITLILID

(END) Dow Jones Newswires

October 11, 2017 02:00 ET (06:00 GMT)

Amphion Innovations (LSE:AMP)
Historical Stock Chart
From Apr 2024 to May 2024